Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Johnson

Family Medicine Helena, MT Doctor of Osteopathy

NPI 1245595081 CMS profile 2781111

2550 E Broadway St, Helena, MT 59601

Open in the dashboard

General payments

$1,187

110 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Johnson of Helena, MT is reported in the CMS Open Payments database as having received $1,187 across 110 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $14 1
2020 General $112 7
2019 General $1,062 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Johnson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Robert Johnson were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Robert Johnson Family Medicine median Middle half National median
2019 $1,062 $150 $41–$543 $163
2020 $112 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $0 $137 $37–$512 $149
2023 $14 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Novo Nordisk Inc $266 17 payments
  2. AstraZeneca Pharmaceuticals LP $141 4 payments
  3. Merck Sharp & Dohme Corporation $139 18 payments
  4. Amgen Inc. $137 13 payments
  5. Janssen Pharmaceuticals, Inc $130 24 payments
  6. Pfizer Inc. $117 13 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $109 11 payments
  8. Novartis Pharmaceuticals Corporation $56 4 payments
  9. Philips Electronics North America Corporation $38 2 payments
  10. Sanofi-Aventis U.S. LLC $29 2 payments
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,187 110 payments
Products named General payments · program years 2019–2023
  1. Ozempic $154 10 payments
  2. FARXIGA $141 4 payments
  3. Tresiba $132 8 payments
  4. XARELTO $121 23 payments
  5. Victoza $112 7 payments
  6. SYMBICORT $106 1 payment
  7. Xultophy 100/3.6 $99 6 payments
  8. CHANTIX $97 11 payments
  9. JANUMET XR $91 11 payments
  10. JANUVIA $91 11 payments
  11. Other $1,231 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 151 drugs

Part D claims

10,956

Median for Family Practice: 1,826

Drug cost

$756,181

Median for Family Practice: $120,094

Branded share of claims

18.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 161 $152,506
Ozempic Semaglutide Brand 88 $103,915
Xarelto Rivaroxaban Brand 49 $48,553
Januvia Sitagliptin Phosphate Brand 53 $47,896
Trulicity Dulaglutide Brand 34 $46,987
Jardiance Empagliflozin Brand 40 $39,595
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 22 $19,658
Victoza 3-Pak Liraglutide Brand 11 $18,917
Farxiga Dapagliflozin Propanediol Brand 17 $18,461
Mounjaro Tirzepatide Brand 14 $16,098

The 10 drugs with the highest cost, of 151 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$99,142

Medicare's payments for the services billed

Medicare patients

485

Average age 74

Services billed

1,412

168 women, 317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 41%
Diabetes 20%
Ischemic heart disease 19%
Atrial fibrillation 16%
Chronic kidney disease 15%
Cancer 15%
Depression 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record